The U.S. Coronary Stents Market Size, Share, Trends & Growth Forecast Report - By Type ( Bare Metal Stents, Drug-Eluting Stents, Bioabsorbable Stents), Mode Of Delivery, Material, End-User, Country (U.S), Industry Analysis From 2025 to 2033
The size of the coronary stents market in the United States is expected to showcase a CAGR of 8.2% from 2025 to 2033.
Coronary stents are small, expandable metal mesh tubes used to treat narrowed or blocked coronary arteries by restoring blood flow to the heart muscle. They are commonly deployed during percutaneous coronary intervention (PCI) procedures for patients suffering from coronary artery disease (CAD). Over the years, technological advancements have led to the development of drug-eluting stents (DES), which release medication to prevent re-narrowing of the artery, significantly improving patient outcomes compared to bare-metal stents (BMS). The U.S. Coronary Stents Market is a well-established segment within the broader cardiovascular device industry, driven by the high prevalence of heart diseases, increasing adoption of minimally invasive procedures, and continuous innovation in stent design and materials. Additionally, as reported by the American Heart Association, approximately 18.2 million adults in the U.S. suffer from some form of coronary artery disease, reinforcing the critical role that coronary stents play in clinical management.
One of the primary drivers of the U.S. Coronary Stents Market is the escalating incidence of cardiovascular diseases (CVDs), particularly coronary artery disease (CAD). As per the Centers for Disease Control and Prevention (CDC), heart disease accounts for about 655,000 deaths annually in the United States, making it the leading cause of mortality nationwide. This growing disease burden has resulted in an increased number of percutaneous coronary interventions (PCIs), where coronary stents are routinely used to restore arterial patency. In 2023 alone, over 750,000 PCI procedures were performed across the country, according to data published by the Society of Cardiovascular Angiography and Interventions (SCAI). Moreover, lifestyle-related risk factors such as obesity, diabetes, and hypertension are contributing to the surge in CAD cases.
Another significant driver fueling the growth of the U.S. Coronary Stents Market is the rapid pace of technological advancements aimed at improving stent performance and reducing complications such as restenosis and thrombosis. Innovations in stent coatings, biodegradable materials, and advanced delivery systems have enhanced procedural success rates and long-term patient outcomes. Companies such as Abbott, Boston Scientific, and Medtronic have been at the forefront of developing ultra-thin strut stents and polymer-free platforms designed to minimize inflammatory responses while maintaining structural integrity. Additionally, the introduction of bioresorbable vascular scaffolds (BVS), although limited due to early technical challenges, has paved the way for future innovations in temporary stent technology. Research conducted by the Cardiovascular Research Foundation reports that ongoing efforts to refine bioabsorbable materials that dissolve after vessel healing, which is offering a promising alternative to permanent metallic implants.
A major restraint affecting the U.S. Coronary Stents Market is the high cost associated with advanced stent technologies, particularly next-generation drug-eluting stents (DES) and emerging bioresorbable vascular scaffolds (BVS). Despite their proven clinical benefits, these premium devices often come with significantly higher price tags compared to conventional bare-metal stents (BMS), posing financial challenges for hospitals and healthcare providers.
According to a 2024 analysis by the Healthcare Cost and Utilization Project (HCUP), the average cost of a DES implantation procedure exceeds USD 15,000, with the stent itself accounting for approximately 30–40% of total expenses. While Medicare and private insurers typically cover coronary stent procedures, reimbursement policies often impose restrictions on the use of newer, costlier stent types unless deemed medically necessary.
Another key restraint impacting the U.S. Coronary Stents Market is the potential for long-term complications associated with stent implantation, including late stent thrombosis, in-stent restenosis, and hypersensitivity reactions. These adverse events have prompted heightened scrutiny from regulatory bodies such as the U.S. Food and Drug Administration (FDA), which requires extensive post-market surveillance and real-world evidence before approving novel stent technologies.
Additionally, past recalls of certain stent models such as Abbott’s Absorb BVS due to elevated rates of adverse cardiac events have further reinforced caution among clinicians and healthcare institutions. As noted by the FDA in its 2023 medical device safety update, any reports of suboptimal clinical performance can lead to delays in product approvals or modifications in labeling recommendations, slowing down market expansion.
A promising opportunity for the U.S. Coronary Stents Market lies in the continued development and refinement of bioresorbable vascular scaffold (BVS) technologies. Unlike traditional metallic stents, BVS devices are designed to provide temporary mechanical support and then dissolve over time, allowing the treated artery to regain its natural function and flexibility. Although early iterations, such as Abbott’s Absorb BVS, faced setbacks due to higher-than-expected rates of late stent thrombosis, recent advancements in material science and scaffold design have reignited interest in this field. According to a 2024 white paper issued by the Cardiovascular Research Foundation, several next-generation BVS prototypes are undergoing clinical trials, demonstrating improved degradation profiles and reduced complication rates. Companies such as ArterioSclerosis Corporation and Elixir Medical are developing magnesium-based and polymer-based scaffolds engineered to optimize vascular healing and minimize inflammation.
Another significant opportunity shaping the future of the U.S. Coronary Stents Market is the integration of artificial intelligence (AI) and machine learning (ML) into stent selection, deployment planning, and procedural optimization. According to a 2024 report by the Mayo Clinic, AI-assisted intravascular imaging techniques such as optical coherence tomography (OCT) and fractional flow reserve computed tomography (FFR-CT) are enhancing pre-procedural planning and intraoperative decision-making. These technologies enable more precise lesion assessment by reducing the risk of under- or over-sizing stents, which can lead to complications such as malapposition or edge dissection.
Additionally, companies like Siemens Healthineers and Philips Healthcare are incorporating AI algorithms into catheterization laboratory workflows to improve procedural efficiency and reduce fluoroscopy time.
A major challenge facing the U.S. Coronary Stents Market is the intense competition among established players, which has led to downward pressure on stent pricing despite the high costs of research and development. Major multinational corporations such as Abbott, Boston Scientific, Medtronic, and Terumo dominate the market, continuously innovating to maintain or expand their market share. Moreover, as highlighted by the Journal of Medical Economics, hospital procurement departments are increasingly leveraging group purchasing organizations (GPOs) to negotiate lower prices for coronary stents. In response, companies are focusing on value-added services such as physician training, data analytics integration, and post-market clinical studies to justify premium pricing.
Another critical challenge confronting the U.S. Coronary Stents Market is the evolving landscape of clinical guidelines, which increasingly emphasize non-invasive treatment approaches for stable coronary artery disease (CAD). Recent studies and guideline updates from organizations such as the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) suggest that optimal medical therapy (OMT) should be prioritized over immediate stent placement in patients with stable angina and moderate ischemia. Consequently, as reported by the Society for Cardiovascular Angiography and Interventions (SCAI), the annual volume of elective stent procedures has seen modest declines in certain regions of the U.S., among low-risk patients. This shift in clinical approach poses a challenge for manufacturers reliant on steady procedural growth, necessitating strategic adaptations such as expanding indications, targeting complex lesions, and emphasizing long-term patient benefits to sustain market momentum.
The Drug-Eluting Stents (DES) segment held a dominant share of the U.S. Coronary Stents Market in 2024. One of the key drivers behind this segment’s dominance is the widespread adoption of DES in percutaneous coronary interventions (PCI) across hospitals and cardiac centers. According to the American College of Cardiology, over 90% of all stent procedures in the U.S. now utilize drug-eluting technology, which is driven by strong clinical evidence supporting their efficacy. The ISCHEMIA trial and other large-scale studies have reinforced the role of DES in preventing re-narrowing of arteries, making them the preferred choice for treating complex lesions.
Additionally, continuous innovation in DES design has further strengthened their position. As reported by the U.S. Food and Drug Administration (FDA), newer-generation DES with ultra-thin struts and biocompatible polymers have demonstrated lower rates of late stent thrombosis and improved vascular healing. Companies such as Abbott, Boston Scientific, and Medtronic have launched advanced DES platforms that offer enhanced deliverability and reduced inflammation.
The Bioabsorbable Stents segment is projected to register a CAGR of 12.6% in the U.S. Coronary Stents Market during the forecast period. Although currently a small portion of the overall market, this segment is gaining traction due to the growing demand for temporary vascular support solutions that dissolve after vessel healing by eliminating the risks associated with permanent metallic implants. Furthermore, there is increasing recognition of the benefits of bioabsorbable stents in younger patients who may require long-term arterial flexibility without the constraints of permanent implants. Companies like Elixir Medical and ArterioSclerosis Corporation are actively advancing new BVS technologies through FDA regulatory pathways.
The Balloon Expandable Stents segment was the largest in the U.S. Coronary Stents Market with significant share in 2024. One of the primary reasons for their continued preference among interventional cardiologists is their proven track record in delivering consistent results during percutaneous coronary interventions (PCIs). Additionally, advancements in delivery systems have enhanced the usability of balloon expandable stents, particularly in tortuous or calcified vessels. As noted by the Cardiovascular Research Foundation, modern low-profile catheters allow for improved navigation through challenging coronary anatomy, expanding the applicability of these stents across diverse patient populations.
The Self-Expanding Stents segment is projected to grow at a CAGR of 11.8% in the U.S. Coronary Stents Market during 2025 to 2033. One of the key factors driving this segment's rapid growth is the increasing utilization of self-expanding stents in peripheral artery disease (PAD) interventions, which often overlap with coronary applications. According to the Society for Vascular Surgery, more than 1.5 million endovascular procedures were performed in the U.S. in 2023, many of which involved self-expanding nitinol-based stents that can be adapted for coronary use.
Moreover, recent technological innovations have led to the development of hybrid coronary stents that combine self-expanding properties with drug-eluting capabilities. A 2024 report by the Journal of Invasive Cardiology highlighted that companies such as Terumo and Biotronik are exploring novel designs tailored for bifurcated lesions and chronic total occlusions (CTOs), where traditional balloon-expandable stents face limitations.
The hospitals segment held the dominant share of the U.S. Coronary Stents Market in 2024. According to the Centers for Disease Control and Prevention (CDC), over 700,000 cardiovascular procedures involving stent placement were conducted in U.S. hospitals in 2023 alone. These facilities provide comprehensive care, including emergency interventions, complex lesion treatments, and post-procedural monitoring, making them the preferred setting for coronary stenting. Additionally, reimbursement policies favor hospital-based interventions, ensuring broader access to premium stent technologies. Data from the Centers for Medicare & Medicaid Services (CMS) shows that inpatient stent procedures receive higher reimbursement rates compared to outpatient settings, reinforcing institutional adoption.
The Ambulatory Surgical Centers (ASCs) segment is projected to register the highest CAGR of 10.9% during the forecast period. According to a 2024 report by the Ambulatory Surgery Center Association (ASCA), the number of ASCs performing minimally invasive cardiovascular procedures increased by 18% year-over-year, with several facilities now approved for elective stent placements under CMS guidelines. The expansion of same-day discharge protocols and improvements in stent technology have enabled safer outpatient interventions. Additionally, advances in imaging modalities and pre-procedural risk stratification have enhanced the feasibility of conducting stent procedures outside traditional hospital settings. Companies like Boston Scientific and Abbott are actively engaging with ASC networks to promote training and adoption of next-generation stents tailored for outpatient use. As regulatory frameworks continue to evolve, the ASC segment is set for rapid expansion in the coronary stents market.
Abbott Laboratories
Abbott has been a global leader in coronary stent technology, particularly with its market-leading drug-eluting stent platforms. The company’s Xience family of stents has set industry benchmarks for safety and efficacy, influencing clinical guidelines and procedural standards worldwide. Abbott continues to innovate by investing heavily in next-generation technologies, including bioresorbable vascular scaffolds and ultra-thin strut designs, which is reinforcing its strong presence in both domestic and international markets.
Boston Scientific Corporation
Boston Scientific is a key player known for its broad portfolio of coronary stents, including the Promus and Synergy platforms. The company has consistently driven advancements in stent design, focusing on improved biocompatibility, reduced inflammation, and enhanced deliverability. With a strong emphasis on clinical research and strategic acquisitions, Boston Scientific has maintained a competitive edge in the U.S. market while expanding its global footprint through partnerships and regulatory approvals across major geographies.
Medtronic plc
Medtronic plays a pivotal role in shaping the coronary stent landscape through continuous innovation and robust R&D initiatives. Its Resolute family of stents remains a preferred choice among interventional cardiologists due to superior long-term outcomes and adaptability to complex lesion treatments. The company also invests in digital health integration, enhancing procedural planning and post-market surveillance, which strengthens its dominant position in the U.S. and supports broader adoption globally.
Strategic Collaborations and Licensing Agreements
Leading players are forming alliances with local manufacturers and research institutions to accelerate product development and expand their regional footprint. These collaborations help companies navigate regulatory landscapes and leverage existing distribution networks in emerging markets.
Innovation-Driven Product Development
Continuous investment in R&D remains central to competitive differentiation. Companies are focusing on enhancing formulation stability, improving drug absorption, and integrating smart delivery mechanisms to meet evolving patient and clinician expectations.
Expansion into Emerging Markets
Leading firms are prioritizing growth in high-potential countries such as India, China, and Southeast Asian nations. This includes setting up local manufacturing units, strengthening supply chains, and aligning with government healthcare initiatives to increase market penetration.
This research report on the U.S. coronary stents market has been segmented and sub-segmented into the following categories.
By Type
By Mode Of Delivery
By Material
By End-User
By Country
Frequently Asked Questions
The growth of the U.S. Coronary Stents Market is being driven by factors such as the increasing prevalence of coronary artery disease, growing adoption of minimally invasive procedures, and advancements in stent technology.
The major players in the U.S. Coronary Stents Market include Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, and Terumo Corporation.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 1200
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region